Bessemer Group
NKTR icon

Bessemer Group’s Nektar Therapeutics NKTR Stock Holding History

Bessemer Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109K Hold
1,565
– – ﹤0.01% 1499
2026
Q1 		$112K Sell
1,565
-15
-0.9% -$854 ﹤0.01% 1495
2025
Q4 		$66K Buy
1,580
+15
+1% +$839 ﹤0.01% 1569
2025
Q3 		$90K Buy
1,565
+1,480
+1,741% +$49K ﹤0.01% 1304
2025
Q2 		$2K Buy
+85
New +$954 ﹤0.01% 2228
2019
Q4 		– Sell
-11
Closed -$3K – 1727
2019
Q3 		$3K Sell
11
-11
-50% -$4.03K ﹤0.01% 1574
2019
Q2 		$12K Sell
22
-23
-51% -$11.5K ﹤0.01% 1469
2019
Q1 		$23K Buy
45
+4
+10% +$2.37K ﹤0.01% 1402
2018
Q4 		$20K Buy
41
+40
+4,000% +$24.1K ﹤0.01% 1513
2018
Q3 		$1K Hold
1
– – ﹤0.01% 1787
2018
Q2 		$1K Buy
+1
New +$1.15K ﹤0.01% 1646
2017
Q1 		– Sell
-5
Closed -$1K – 1860
2016
Q4 		$1K Buy
5
+1
+25% +$203 ﹤0.01% 1900
2016
Q3 		$1K Hold
4
– – ﹤0.01% 1768
2016
Q2 		$1K Sell
4
-368
-99% -$82.3K ﹤0.01% 1271
2016
Q1 		$77K Buy
372
+368
+9,200% +$70.7K ﹤0.01% 826
2015
Q4 		$1K Sell
4
-185
-98% -$38K ﹤0.01% 1537
2015
Q3 		$31K Hold
189
– – ﹤0.01% 1040
2015
Q2 		$36K Hold
189
– – ﹤0.01% 1034
2015
Q1 		$32K Hold
189
– – ﹤0.01% 1052
2014
Q4 		$44K Buy
+189
New +$40.4K ﹤0.01% 962

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bessemer Group's NKTR Position: Q2 2026 in Review

Bessemer Group held its Nektar Therapeutics (NKTR) position steady in Q2 2026 at 1,565 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #1499.

Bessemer Group first reported a position in NKTR in Q4 2014 and has held it in 20 quarters since. The position peaked at $112K in Q1 2026. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Bessemer Group held 1,565 shares of Nektar Therapeutics worth $109K as of Q2 2026.
  • Bessemer Group left its Nektar Therapeutics share count unchanged in Q2 2026.
  • Nektar Therapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #1499 holding.
  • Bessemer Group first reported a position in Nektar Therapeutics in Q4 2014 and has held it in 20 quarters since.
  • Bessemer Group's Nektar Therapeutics position peaked at $112K in Q1 2026.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.